Kairos Pharma, LTD.(KAPA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KAPA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Kairos Pharma, LTD. (KAPA), a Healthcare sector company. KAPA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of KAPA by reported 13-F value include CITADEL ADVISORS, VANGUARD CAPITAL MANAGEMENT, Virtu Financial, based on the most recent SEC filings. KAPA trades on the NYSE exchange and files with the SEC under CIK 1962011. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KAPA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kairos Pharma, LTD. directly from SEC EDGAR.
Net Income
Q2 2026
$-1.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-109.3% YoYOperating Income
-137.8% YoYEPS (Diluted)
-30.4% YoYTotal Assets
+13.4% YoYOp. Cash Flow
+13.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-5.4M -109.3% | $-2.6M -43.7% | $-1.8M | — |
| Operating Income | $-5.6M -137.8% | $-2.3M -36.7% | $-1.7M | — |
| EPS (Diluted) | $-0.30 -30.4% | $-0.23 -35.3% | $-0.17 | — |
| Total Assets | $6.5M +13.4% | $5.8M +497.7% | $965.0K | — |
| Operating Cash Flow | $-3.4M +13.0% | $-4.0M -4982.7% | $81.0K | — |
Get alerted when KAPA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kairos Pharma, LTD. including:
Top Institutional Holders of KAPA
CITADEL ADVISORS LLC
$118.9K309,834 shVANGUARD CAPITAL MANAGEMENT LLC
$89.0K231,878 shVirtu Financial LLC
$31.0K82,092 shGEODE CAPITAL MANAGEMENT, LLC
$30.3K78,924 shVANGUARD FIDUCIARY TRUST CO
$24.5K63,884 shSevenBridge Financial Group, LLC
$17.1K44,286 shAptus Capital Advisors, LLC
$17.0K44,286 shJANE STREET GROUP, LLC
$12.9K33,749 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$11.2K29,292 shSTATE STREET CORP
$9.2K24,100 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $118.9K | 309,834 |
| VANGUARD CAPITAL MANAGEMENT LLC | $89.0K | 231,878 |
| Virtu Financial LLC | $31.0K | 82,092 |
| GEODE CAPITAL MANAGEMENT, LLC | $30.3K | 78,924 |
| VANGUARD FIDUCIARY TRUST CO | $24.5K | 63,884 |
| SevenBridge Financial Group, LLC | $17.1K | 44,286 |
| Aptus Capital Advisors, LLC | $17.0K | 44,286 |
| JANE STREET GROUP, LLC | $12.9K | 33,749 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.2K | 29,292 |
| STATE STREET CORP | $9.2K | 24,100 |
More Healthcare Companies
View all Healthcare →Put KAPA on your watchlist
Track score changes the day Kairos Pharma, LTD. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KAPA a good stock to buy?
13F Pro's AI-powered analysis of Kairos Pharma, LTD. (KAPA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KAPA are available on the KAPA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KAPA is classified as a small company.
Which hedge funds own KAPA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KAPA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kairos Pharma, LTD.'s investment landscape.